IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 37,647 new ordinary shares of 0.1p each ("New Shares") to satisfy the exercise of options.
The New Shares are expected to be admitted to trading on AIM on 29 August 2019.
Total voting rights
Application has been made for admission to trading on AIM of 37,647 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 29 August 2019, following which there will be in total 46,814,647 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.
This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.
For further information please contact:
+44 (0) 20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)
+44 (0) 20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Optimum Strategic Communications
+44 (0) 203 950 9144
Mary Clark / Anne Marieke Ezendam / Supriya Mathur
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
IXICO PLC's (LON:IXI) Giulio Cerroni sat down with Proactive London's Andrew Scott after reporting its first year of profitability since its admission to AIM .
For the year ended 30 September, the neuroscience analytics firm swung to an underlying (EBITDA) profit of £500,000 from a £600,000...